GlaxoSmithKline

A Tropical Disease Research by GSK Partners and Brazil's Fiocruz

GlaxoSmithKline and the Brazil-based Oswald Cruz Foundation (Fiocruz) are due to carry out some effective research and come up with some new medicines for tropical diseases Chagas and leishmaniasis.

GSK's R&D hub in Tres Cantos Campus, Spain would be sued for the purpose as it is said to have its `Open Lab', concept there which had been set up in the month of January by the manufacturer.

The whole idea behind it was to enable information exchange between scientists worldwide, who are busy searching for treatments for diseases of the developing world, individually.

Companies: 

QA Manager Sent to Puerto Rico Drug-Making Plant to Deal with Violation Problem

In 2002, pharmaceutical Company GlaxoSmithKline PLC sent Cheryl Eckard to Puerto Rico to tackle the violation problem in one of its biggest drug-making plants.

The U. S. authorities had warned that the plant is not abiding by the standards to make drugs and ointments, including one that was made to treat skin-related infections in children.

Ms. Eckard has received that the largest amount of payment or reward for whistleblowing so far in the history of the United States.

Companies: 
General: 

Quality Assurance Manager Rewarded for Whistleblowing

After the pharmaceutical Company GlaxoSmithKline PLC needed to reassess one of their manufacturing plants in Puerto Rico, they sent one of the Company’s quality assurance managers Cheryl Eckard. The former employee of the Company exposed severe abuses such as the production of a skin product for children that was poisonous.

Furthermore, Ms. Eckard observed that drugs often were mixed up in the same bottles in Puerto Rico, a dangerous mistake that has not been corrected.

General: 
Companies: 

GSK to Shell out $750Million for Providing Substandard Medicines

The British pharmaceutical Company, GlaxoSmithKline has finally decided to reach a settlement regarding the numerous criminal lawsuits and civil complaints. GSK would be shelling out compensation amounting to $750million for selling contaminated baby lotion for years, despite knowing that the ointment was not fit for use.

Companies: 
General: 

GlaxoSmithKline Forms Alliance for Rare Disease Research

GlaxoSmithKline has announced a new alliance with Italy-based Fondazione Telethon and Fondazione San Raffaele in order to boost its research on treatments for rare diseases.

The two Italian firms focus their work on ADA Seyer Combined Immune Deficiency, a rare genetic disorder that affects about 350 children around the world. Through the partnership GlaxoSmithKline intends to bolster its rare disease research unit. This unit will focus on diseases to which research can "realistically" make a significant contribution, says unit head Marc Dunoyer.

Region: 
General: 
Companies: 

Pages

Subscribe to RSS - GlaxoSmithKline